Integration of MRI radiomics with immune profiling to predict response to CDK6 inhibitors in high-grade glioma

Background

Predictive biomarkers are needed to identify patients with high-grade glioma who benefit from cyclin-dependent kinase 6 (CDK6) inhibition. We hypothesized that an integrated Radiomics-Immune Score (R/I-Score), combining MRI-derived tumor heterogeneity with peripheral immune profiling, would predict progression-free survival (PFS) benefit from CDK6 inhibitor-containing therapy (CDK6i).